Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ruvise

Novartis building

Novartis to deliver three million malaria treatments in Zambia

Part of Malaria No More’s Power of One campaign

Novartis building

Novartis faces FDA rejection for myeloma drug

Concerns over toxicity of panobinostat

Biogen Idec building

EMA starts review of Biogen Idec’s haemophilia A therapy

Elocta already on the market in the US, Canada and Australia

- PMLiVE

Pfizer gets FDA nod for meningitis vaccine Trumenba

Ahead of Novartis’ rival drug Bexsero

Novartis building

Novartis sells flu vaccines business to CSL for $275m

Follows the Swiss pharma company's asset swap deals with GSK

- PMLiVE

Orphan drugs lead CHMP recommendations

Clinuvel's Scenesse is first drug set for European approval to treat rare intolerance to sunlight

Novartis building

FDA panel backs Novartis’ secukinumab for psoriasis

Drug has outperformed Amgen’s Enbrel in clinical trials

- PMLiVE

EMA offers orphan drug benefits for Ebola research

Incentives to encourage development of new treatments for the virus

EMA expands adverse event reporting website

Opens it up to all nationally-authorised medicines

- PMLiVE

EMA safety panel rules no change needed for Ariad’s Iclusig

Positive news comes after blood clot concerns

Novartis building

Novartis’ secukinumab has ‘consistent’ activity in psoriasis

Reinforces data that suggests drug is more effective than Amgen’s Enbrel

- PMLiVE

Novartis announces departures of three execs

Follows deals to sell divisions to GSK and Lilly

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links